Kornimate/medical-research-clean huggingface dataset:
collection and storage of tissue samples from patients undergoing surgery for suspected solid tumors

Conditions: Unspecified Adult Solid Tumor, Protocol Specific; Unspecified Childhood Solid Tumor, Protocol Specific

Summary: rationale: collecting and storing samples of tissue or blood from patients with cancer for study in the laboratory may help the study of cancer in the future purpose: this research study is collecting and storing blood and tissue samples from patients with suspected solid tumors.

objectives: * to provide a tissue and cell repository to be used by wake forest university comprehensive cancer center (wfuccc) investigators. * to provide specialized research pathology services to these investigators. outline: tumor and normal tissue in the resected specimen (when possible) are harvested and collected from patients undergoing planned surgery or biopsy. additionally, any normal tissue and/or fluid removed in the course of the operation (e.g., cerebrospinal fluid during brain tumor resection) may also be stored for use in analyzing changes from normal tissue to cancerous tissue. specimens are rapidly frozen in liquid nitrogen to preserve the mrna, proteins, lipids, and dna in the samples for future analysis. tissue is stored for research projects on tumors and treatment of cancer patients. research may involve analysis of the genetic makeup of the tumor tissue. genes may be cloned and living cells cultured from the stored tissue. blood is also collected during surgery. samples are maintained and cataloged for future retrieval. information about medical history is collected from patient medical records. this information includes the following: medical diagnosis; specific information about treatment; other medical conditions; medical data (i.e., laboratory test results, tumor measurements, ct scans, mri scans, x-rays, and pathology results); side effects experienced and treatment for side effects; long-term information about general health status and the status of disease; data that may be related to tissue and/or blood samples collected; and identifying numbers or codes (i.e., social security number and medical record number).

Eligibility criteria:
inclusion criteria: * clinically suspected solid tumor and scheduled for surgical resection and/or biopsy

Keywords: unspecified adult solid tumor, protocol specific unspecified childhood solid tumor, protocol specific
dose-finding, safety and efficacy study of nv1fgf in patients with intermittent claudication

Conditions: Peripheral Arterial Occlusive Disease

Summary: the primary objective is to assess safety and efficacy of two different doses of nv1fgf as compared to placebo. the secondary objective is to assess the pharmacokinetics of nv1fgf and fgf-1 protein.

screening of 1 to 4 weeks before study drug administration; 6 weeks of treatment, followed by 20 weeks of follow-up.

Eligibility criteria:
inclusion criteria: * age\>40 years * history of typical intermittent claudication lasting for at least 3 months, showing no improvement and consistent with treadmill test findings * objective evidence of peripheral arterial occlusive disease. after 10 minutes of rest, either by ankle brachial index measure (abi) \<0.8 or systolic ankle pressure (ap) \< 50 mmhg or systolic toe pressure \<50 mmhg * patent femoral inflow above the level of injections recently (\<2 weeks) documented either with doppler ultrasonography or magnetic resonance angiography or angiography exclusion criteria: * evidence of other causes for leg pain other than intermittent claudication. * illnesses limiting subject exercise capacity (angina pectoris, heart failure, respiratory disease, orthopaedic disease, neurological disorders...) * pain at rest * buerger's disease * positive serology for hiv 1 or 2, positive serology hepatitis b or c. * subjects with serum creatinine \> 2 mg/dl (176 µmol/l) and subjects on dialysis. * active proliferative retinopathy defined by the presence of new vessel formation and scarring. * subjects who had a stroke or neurologic deficit presumed to be due to stroke within 3 months prior to the first administration of study treatment * previous treatment with any angiogenic growth factor * pregnant or breast feeding women or who disagree to practice a medically accepted method of birth control. men and women who do not agree to use condoms as the only accepted protection barrier, for the entire study period * serious concomitant medical conditions not adequately controlled. * current alcohol or drug abuse the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
study on the effectiveness of an emollient cream containing pre and postbiotic and niacinamide 4% in the treatment of skin xerosis and itching in oncological patients treated with anti-egfr

Conditions: Xerosis Cutis

Summary: study on the effectiveness of an emollient cream containing pre and postbiotic and niacinamide 4% in the treatment of skin xerosis and itching in oncological patients treated with anti-egfr.

epidermal growth factor receptor inhibitors (egfri) are drugs approved as treatment options in several solid tumors, such as advanced colon, head-neck, breast and lung cancers, because overexpression or mutation of egfr is implicated in the pathogenesis of these types of cancer. egfr, in addition to being expressed by neoplastic cells, is also present constitutively on basal keratinocytes, and its inhibition can determine in these cells apoptotic effects, cell growth inhibition, alteration of physiological cell migration and inflammatory processes through the release of pro-inflammatory cytokines, recruitment of leukocytes and the release of pro-apoptotic molecules. among the possible adverse skin events (cae), the papulo-pustular rash is the most frequent in the course of therapy with egfri (45-90%). in addition to the papulopustulous rash, xerosis and itching are the main dermatological ae associated with egfri therapy, with a significant negative impact on the quality of life (qol) of cancer patients. the reduction of itching and subsequent scratching can therefore be effective in preventing the exacerbation of skin lesions and improving qol in cancer patients, especially in those who experience intense skin xerosis. emollients containing urea and ceramides have proved useful in skin hydration in case of cutaneous xerosis and in attenuating the associated itching. however, there are few articles in the literature that compare the moisturizing and antipruritic effects of the various basic components of emollients, especially in patients undergoing oncological treatment with egfri. the goals are to examine the effectiveness of an emollient cream containing the prebiotic α-glucan oligosaccharide, the postbiotic lactobacillus ferment pure (obtained by patented extraction method bptech) and niacinamide 4%, in the treatment of xerosis, and to test the effectiveness and superiority of this topical preparation in skin hydration and in soothing pruritic symptoms compared to a 10% urea cream commonly used in clinical practice in patients with skin xerosis.

Eligibility criteria:
inclusion criteria: 1. patients aged 18 who have been receiving anti-egfr therapy for more than three months, 2. signature of the informed consent. exclusion criteria: 1. patients diagnosed with grade ii papulopustulous skin reaction according to the common terminology criteria for adverse event (ctcae) scale at the time of enrolment; 2. concomitant use of emollients and/or steroidal creams; 3. personal history of xerotic pathologies (e.g. lichen, ichthyosis) and/or itching of n.d.d.; 4. inability to provide informed consent or inability to complete the procedures required for enrollment in the study.
the function of gastrointestinal tract during pregnancy

Conditions: Constipation

Summary: in this prospective study the function of gastrointestinal tract was assessed using constipation questionnaire (rome criteria and bowel function index).


Eligibility criteria:
inclusion criteria: * informed consent obtained * pregnancy, delivery * female non pregnant exclusion criteria: * no informed consent * male

Keywords: constipation pregnancy delivery
adjuvanted influenza vaccine effectiveness in the elderly (65+yrs)

Conditions: Influenza

Summary: this study explores the hypothesis that the use of an adjuvanted influenza vaccine in the elderly will produce greater vaccine effectiveness in their group.

to evaluate the effectiveness of adjuvanted trivalent inactivated influenza vaccine in the elderly (aged ≥ 65 years) through the reduction in relative risk of microbiologically confirmed influenza illness

Eligibility criteria:
inclusion criteria: 1.elderly tested for influenza as part of routine clinical care in the lower mainland and on vancouver island during the influenza season. cases: proven influenza diagnosed on naso-pharyngeal swab via pcr controls: elderly with influenza-like-illness testing negative for influenza during the influenza season. exclusion criteria: 1. known immunodeficiency disorders (including hiv) 2. current or recent (within 90 days prior to first dose of influenza vaccine) immunosuppressive treatment including chronic oral steroids (1mg/kg for \> 4 weeks), cytotoxic chemotherapy, radiation therapy, other immunosuppressive drug and biologic agents note: use of topical or inhalant corticosteroids is acceptable. 3. administration of immunoglobulins during the study period;
long term follow-up after embolization of brain arteriovenous malformations

Conditions: Arteriovenous Malformations

Summary: the time-frame and the follow-up elements after embolization of brain arteriovenous malformations are not standardized. therefore, few reliable follow-up data are available for these patients. this study aims at collecting standardized long term data for these patients.


Eligibility criteria:
inclusion criteria: * arteriovenous malformation * age \> 18 years old exclusion criteria: * none
is the expression of the glut5 specific fructose transport protein abnormal in patients with fructose intolerance?

Conditions: Irritable Bowel Syndrome; Fructose Intolerance

Summary: in this study we will investigate the expression of the fructose transport protein glut5 in the small intestine in patients with functional gi disoders and fructose intolerance compared to matched healthy controls.

intolerances to food are a major complaint of patients with functional gastrointestinal disorders (fgid) and even commoner in patients with inflammatory bowel disorders (ibd) (barrett js et al. aliment pharmacol therap 2009;30:165-174). the most common forms of food intolerance are fodmap (fermentable oligo-, di- and monosaccharide and polyol) -related, of which fructose and lactose are the best known. the prevalence of lactose and fructose intolerance in ibs patients is between 50 and 70% (wilder-smith ch et al. gastroenterology 2009;136 (suppl. 1): a324). recent high quality studies have shown that the reduction of ingested fodmap can lead to significant and long-term symptom improvement in patients shown to be intolerant by breath-testing. while the pathophysiology behind lactose intolerance is the reduction in small intestinal lactase availability, the mechanism in fructose intolerance and its relationship to malabsorption are unknown. one possible and so far uninvestigated mechanism is a reduction in the expression or activity of the specific fructose transporter, glut5, which is mainly responsible for luminal absorption of fructose. glut5 is mainly found in the small intestine, as well as various extra-intestinal organs. the clinical relevance of glut5 expression for food intolerances in humans has not been reported, but in a mouse model deletion of glut5 led to decreased absorption of dietary fructose and typical signs of malabsorption (barone s et al. j biol chem 2009;284:5056-5066). the control of glut5 is dynamic and considerable upregulation together with increased absorption of fructose is evident in diabetes mellitus, while expression is decreased by inflammation and lipopolysaccharide endotoxin, an integral component of the outer membrane of all gram-negative bacteria, through the action of pro-inflammatory cytokines, such as tfn-a.

Eligibility criteria:
inclusion criteria: * patients referred to our practice for evaluation of symptoms consistent with fgid undergoing upper gi endoscopy with biopsy and fructose breath testing as part of their usual clinical evaluation. male or female patients aged between 18 and 60 years with fgid (irritable bowel syndrome (ibs), functional dyspepsia (fd) or functional bloating (fb), as defined by rome iii criteria. * successive patients without fructose intolerance undergoing upper gi endoscopy for other reasons without inflammatory disease exclusion criteria: * inflammatory gi disease, coeliac's disease, other relevant systemic disorders as judged by investigator, concomitant antiinflammtory treatments, absent informed consent.

Keywords: ibs fructose intolerance glut 5 glut 2
multi merci (mechanical embolus removal in cerebral ischemia [merci™])

Conditions: Ischemic Stroke

Summary: the primary objectives of the multi merci trial were: * to evaluate the addition of the merci l5 retriever * additionally permit use of the merci retrieval system in the setting of persistent clot following iv t-pa treatment (use in the 0-8 hour window for patients ineligible for iv t-pa was also permitted)

per the multi merci protocol, up to 230 patients could be treated at up to 30 centers. the intended trial indication for the merci l5 retriever was to restore blood flow in the neurovasculature by removing thrombus in patients experiencing ischemic stroke. patients that were contraindicated or failed treatment with intravenous t-pa were allowed to be enrolled under the multi merci protocol. per the multi merci protocol, following inclusion of the merci l5 retriever the operating physician was required to initiate treatment with the merci l5 retriever. at the physician's discretion, subsequent passes could be made with the merci l5 retriever, merci x6 retriever and/or merci x5 retriever. adverse events were adjudicated by an independent data safety and monitoring board (capital dsmb).

Eligibility criteria:
inclusion criteria: * angiographically confirmed large vessel ischemic stroke (occlusion may include the following: internal carotid artery (ica), m1/m2, vertebral, or basilar arteries) * intervention is able to be performed within 8 hours of symptom onset * patients \> 18 years of age * nihss score 8+ * failed iv t-pa treatment or contraindicated for iv t-pa exclusion criteria: * international normalized ratio (inr) \> 3.0 * platelet count \< 30,000 * heparin use in previous 24 hours with ptt \> 2x normal * baseline bloog glucose \< 50 mg/dl * baseline computed tomography (ct) showing mass effect with midline shift * severe sustained hypertension (sbp \> 185 or dbp \> 110) that cannot be controlled with medication * patient is pregnant, has anticipated life expectancy \< 3 months, or has severe allergy to contrast medium * arterial stenosis \> 50% proximal to embolus * excessive arterial tortuosity that precludes the study device from reaching the target area

Keywords: stroke ischemic thrombus embolectomy thrombectomy merci concentric embolus embolism mechanical
factors associated with success of nippv in als patients

Conditions: ALS

Summary: this is a retrospective cohort study to assess the factor associated with success of non-invasive positive ventilation in als patients.

patients with als who were admitted to a tertiary hospital for initially applying non-invasive positive pressure ventilation (nippv). the objective of this study was to investigate factors associated with optimal nippv initiation and adherence, and to assess the long-term effects of nippv adherence in als patients.

Eligibility criteria:
inclusion criteria: * patients fulfilling the el escorial world federation criteria for probable, or definite als * aged ≥ 19 years * patients who performed blood gas analysis including venous blood gas and arterial blood gas before nippv application. exclusion criteria: * patients who had experience in applying the nippv or currently using nippv * patients who applied in outpatient settings * patients who did not perform blood gas analysis before nippv application * patietns who had a history of asthma or copd, * patients who didn't have any record of nippv application time

Keywords: noninvasive positive pressure ventilation amyotrophic lateral sclerosis adherence
mobile enhancement of motivation in schizophrenia

Conditions: Schizophrenia; Schizo Affective Disorder; Psychosis

Summary: motivation deficits are a strong determinant of poor functional outcomes in people with schizophrenia. mobile interventions are a promising approach to improving these deficits, as they can provide frequent cues and reinforcements that support goal-directed behavior. the primary aims of this study are to conduct a pilot study using a randomized design to 1) test the feasibility and acceptability of a personalized mobile text message intervention, mobile enhancement of motivation in schizophrenia (mems) and to 2) test the preliminary effectiveness of mems compared to a control condition.

objectives: motivation deficits are one of the strongest determinants of poor functional outcomes in people with schizophrenia. mobile interventions are a promising approach to improving these deficits, as they can provide frequent cues and reinforcements that support goal-directed behavior. the objective of this study is to conduct a pilot study using a randomized design to 1) test the feasibility and acceptability of a personalized mobile text message intervention, mobile enhancement of motivation in schizophrenia (mems) and to 2) test the preliminary effectiveness of mems compared to a control condition. methods: up to forty outpatients with a schizophrenia-spectrum disorder will be recruited. all participants will set individualized recovery goals to complete over an eight-week period; those randomized to receive mems will also receive three sets of personalized, interactive text messages each weekday to reinforce and cue goal completion. before and after the eight-week period, participants in both groups will complete validated measures of motivation. both groups will also report their goal attainment after eight weeks. results: it is anticipated that those in the mems group will demonstrate greater goal attainment and improvements in motivation compared to the control group. discussion: this project will test the initial feasibility, acceptability, and effectiveness of a novel intervention for improving one of the most debilitating aspects of schizophrenia.

Eligibility criteria:
inclusion criteria: * schizophrenia-spectrum diagnosis * have a text-message enabled cell-phone * are a current client at a participating community mental health center * are in a non-acute phase of illness or have no medication changes or hospitalizations in the prior 30 days * demonstrate a minimum of moderate motivation impairments according to the clinical assessment interview for negative symptoms (cains; kring et al., 2013) * have an english reading level at or above the fourth grade according to the graded word list (pray \& ross, 1969)
cardiovascular comorbidities and bronchiectasis

Conditions: Bronchiectasis

Summary: bronchiectasis have multiple etiologies but share a similar bronchial injury associated with inflammation, which leads to a progressive lung deterioration. this disease is responsible for a frequent access to care with an exacerbation rate of 1.8 per year with a high risk of hospitalization. natural history is marked by recurrent infectious diseases which are the main prognosis factor. this disease is associated with an inflammation rate in the lung as well as in the blood. up to now, no study has been described comorbidities associated with this chronic disease but our hypothesis is that cardiovascular diseases will be more frequent in these patients. in fact systemic inflammation driven by bronchial infections may increase frequency of cardiovascular diseases. the investigators decide to conduct a monocentric observational study to define the prevalence and characterization of cardiovascular comorbidities as well as markers of accelerated aging. we would like to test the hypothesis that cardiovascular comorbidities are frequent in bronchiectasis and may be associated with markers of inflammation and aging. phenotype of the lung disease will include: spirometry, plethysmography, dlco measurement according to the ats/ers guideline. 6m walking test and echocardiography will be also performed. frequency of comorbidities will be calculated with data from questionnaire as well as standardized explorations. aging related manifestations will be measured: arterial stiffness using aortic pulse wave velocity, bone mineral density using dual energy x-ray absorptiometry. appendicular skeletal muscle mass and grip test were also performed. blood test were also performed to measure inflammatory markers, cytokines and length of telomere in circulating leucocytes.

phenotype of the lung disease will include: spirometry, plethysmography, dlco measurement according to the ats/ers guideline. 6m walking test and echocardiography will be also performed. frequency of comorbidities will be calculated with data from questionnaire as well as standardized explorations. aging related manifestations will be measured: arterial stiffness using aortic pulse wave velocity, bone mineral density using dual energy x-ray absorptiometry. appendicular skeletal muscle mass and grip test were also performed. blood test were also performed to measure inflammatory markers, cytokines and length of telomere in circulating leucocytes.

Eligibility criteria:
inclusion criteria: * 40 ≤ age ≤ 80 years * formal diagnosis of bronchiectasis by imaging (ct-scan) * for women, pregnancy test negative * affiliation to a social security * written inform consent exclusion criteria: * patients with a diagnosis of cystic fibrosis * contre indication of one of the tests * exacerbation with hospitalization or outpatient clinic visit in the last 4 weeks. * unability to obtain an informed consent * pregnancy or breast feeding